Skip to main content
. Author manuscript; available in PMC: 2009 Oct 25.
Published in final edited form as: Exp Neurol. 2005 Dec 9;197(2):363–372. doi: 10.1016/j.expneurol.2005.10.022

Fig. 6.

Fig. 6

Response of AAV-AADC-treated and control monkeys to chronic l-dopa. Sinemet CR was given BID for 5 weeks. The therapeutic dose of l-dopa was determined for each monkey and adjusted to one of the following doses: 50/200 mg, 25/100 mg, 12.5/50 mg (l-dopa/Carbidopa) to avoid or minimize dyskinesias or other adverse effects of l-dopa administration. (A and B) Clinical improvement in response to l-dopa administration was achieved in 2 NHP treated with AAV-NULL without inducing dyskinesias. However, the AADC-treated group developed dyskinesias in the first 5 days of treatment that persisted despite lowering the dose of Sinemet. Both groups had some degree of other adverse effects of l-dopa treatment such as hyperactivity, aggression, occasional apparent hallucinations and self-mutilation. (C and D) Eight monkeys, in which diffuse transgene expression (NULL or AADC; n = 4 in each group) was achieved, were subjected to a similar regimen of Sinemet CR for 7 weeks. No dyskinesias were observed in response to either acute or chronic l-dopa.